Sanofi announces it has entered into a definitive agreement to acquire ownership of Qunol, a US-based, market-leading brand in health & wellness. This transaction will strengthen Sanofi’s Consumer Healthcare’s (CHC) vitamin, mineral and supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the US, focusing on the active ‘healthy aging’ segment. With Qunol’s CoQ10 in heart health and turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its US portfolio, focused on chronic conditions with growing consumer demand. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van Ongevalle, executive vice president, consumer healthcare, Sanofi, said: “The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our US presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
Qunol CoQ10 and turmeric products are both backed by science literature and strong market positioning in their segments. Qunol’s high product quality and efficacy have resulted in strong brand equity among consumers and customers, as well as above category consumer loyalty. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the US.
Peter Boutros, CEO, Quten Research Institute, LLC, said: “Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the US and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
Founded in 2006 with the goal of delivering efficacious, science-backed health solutions, Qunol is a market leader in the VMS industry and at the forefront of the fast-growing healthy aging sector. The brand's CoQ10 and Turmeric products are differentiated solutions that combine high-quality ingredients with unique absorption technology to deliver powerful support for heart health and joint health respectively. Qunol's products enjoy multiple #1 market positions across leading Club, Mass and Ecommerce retailers in North America.
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!